Sildenafil Citrate
FDA-approved product (tablet, oral), marketed as Liqrev, Revatio, Sildenafil Citrate and 2 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Connective tissue disease
- Erectile dysfunction
- Idiopathic and/or familial pulmonary arterial hypertension
- Impotence
- Pulmonary arterial hypertension
- Pulmonary hypertension
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Drugs used in erectile dysfunction
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA46.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli42.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae39.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Sildenafil Citrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Blood Pressure Interaction Between Sildenafil and Sublingual Glyceryl Trinitrate (GTN) in Men With Angina
NCT00479908 · start 2004-01
Registered record
- Registry ID
- NCT00479908
- Conditions
- Angina Pectoris
- Interventions
- Sildenafil citrate; Glyceryl trinitrate
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2004-01
- Completion
- 2005-09
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAngina PectorisInterventionSildenafil citrate; Glyceryl trinitratePhasePhase 4Registry statusCompletedA Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes
NCT00645268 · start 2002-12
Registered record
- Registry ID
- NCT00645268
- Conditions
- Erectile Dysfunction; Diabetes Mellitus, Type 2
- Interventions
- sildenafil; placebo; sildenafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2002-12
- Completion
- 2004-01
- Enrolment
- 300
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile Dysfunction; Diabetes Mellitus, Type 2Interventionsildenafil; placebo; sildenafilPhasePhase 4Registry statusCompletedEfficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension
NCT00155714 · start 2002-11
Registered record
- Registry ID
- NCT00155714
- Conditions
- Primary and Secondary Pulmonary Hypertension
- Interventions
- type-5 phosphodiesterase Inhibitor (Sildenafil)
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Withdrawn
- Start
- 2002-11
- Completion
- 2005-05
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPrimary and Secondary Pulmonary HypertensionInterventiontype-5 phosphodiesterase Inhibitor (Sildenafil)PhaseNot applicableRegistry statusWithdrawnA Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension
NCT00644605 · start 2002-10
Registered record
- Registry ID
- NCT00644605
- Conditions
- Hypertension, Pulmonary
- Interventions
- sildenafil; sildenafil; placebo; sildenafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2002-10
- Completion
- 2003-11
- Enrolment
- 275
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertension, PulmonaryInterventionsildenafil; sildenafil; placebo; sildenafilPhasePhase 3Registry statusCompletedA Study Evaluating the Efficacy and Safety of Sildenafil in Patients With Erectile Dysfunction Receiving Hemodialysis
NCT00654017 · start 2002-10
Registered record
- Registry ID
- NCT00654017
- Conditions
- Erectile Disfunction; Hemodialysis
- Interventions
- placebo; sildenafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2002-10
- Completion
- 2005-04
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile Disfunction; HemodialysisInterventionplacebo; sildenafilPhasePhase 4Registry statusCompleted